NCT04439123 2026-05-06Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled 10 charts